Exploring the Clinical Stage TGF-β Fusion Protein Expressing Oncolytic Virus, AdAPT-001
Time: 9:00 am
day: Day Two
Details:
- Highlighting the safety and tolerability of TGF-β targeting OV, AdAPT-001
- Using correlative studies for measuring expression in the clinic
- Discussing neutralizing TGF-β for improving checkpoint inhibitors